logo

For the Inventor, By the Inventor

San Diego, CA, United States of America

Chin-Chun Lu

USPTO Granted Patents = 15 

Average Co-Inventor Count = 2.6

ph-index = 4

Forward Citations = 26(Granted Patents)


Company Filing History:

goldMedal9 out of 4,770 
 
Merck + Co., Inc.
 patents
silverMedal3 out of 48 
 
Sibia Neurosciences, Inc.
 patents
bronzeMedal2 out of 549 
 
Celgene Corporation
 patents
4. 1 out of 48 
 
Fate Therapeutics, Inc.
 patents

Years Active: 1998-2025

Loading Chart...
15 patents (USPTO):Explore Patents
1. 12486281 - Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith (2025-12-02),
2. 11306101 - Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith (2022-04-19),
3. 9370510 - Small molecule compounds to treat hearing loss (2016-06-21),
4. 6956102 - Human N-methyl-D-aspartate receptor subunits nucleic acids encoding same and uses therefor (2005-10-18),
5. 6864358 - Human n-methyl-d-aspartate receptor subunits, nucleic acids encoding same and uses therefor (2005-03-08),
6. 6825322 - Human N-methyl-D-aspartate receptor subunits, nucleic acids encoding same and uses therefor (2004-11-30),
7. 6521413 - Human N-methyl-D-aspartate receptor subnits, nucleic acids encoding same and uses therefor (2003-02-18),
8. 6469142 - Human N-methyl-D-aspartate receptor subunits, nucleic acids encoding same and uses therefor (2002-10-22),
9. 6376660 - Human N-methyl-D-aspartate receptor subunits, nucleic acids encoding same and uses therefor (2002-04-23),
10. 6362316 - Human metabotropic glutamate receptor subtype mGluR6 protein (2002-03-26),
11. 6316611 - Human N-methyl-D-aspartate receptor subunits, nucleic acids encoding same and uses therefor (2001-11-13),
12. 6111091 - Human N-methyl-D-aspartate receptor subunits, nucleic acids encoding (2000-08-29),
13. 5985586 - Methods for identifying compounds that modulate the activity of human (1999-11-16),
14. 5912122 - Nucleic acids encoding and method for detecting nucleic acid encoding (1999-06-15),
15. 5849895 - Human N-methyl-D-aspartate receptor subunits, nucleic acids encoding (1998-12-15),

Title: Chin-Chun Lu: Innovator in Hearing Loss Treatment

Introduction

Chin-Chun Lu is a prominent inventor based in San Diego, CA, known for his significant contributions to the field of medical science. With a total of 15 patents, he has made remarkable advancements, particularly in the treatment of hearing loss. His innovative work has garnered attention in both academic and commercial sectors.

Latest Patents

Among his latest patents, Chin-Chun Lu has developed substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith. This invention focuses on small molecule compounds designed to treat or prevent hearing loss. The compositions not only aim to address hearing loss but also promote sensory hair cell regeneration. Notably, some of these compositions include ellipticine derivatives and may incorporate small molecules that enhance Atoh1 expression or activity, along with various growth factors.

Career Highlights

Chin-Chun Lu has had a distinguished career, working with leading companies in the pharmaceutical and neuroscience sectors. He has been associated with Merck & Company, Inc. and Sibia Neurosciences, Inc., where he has contributed to groundbreaking research and development efforts.

Collaborations

Throughout his career, Chin-Chun Lu has collaborated with notable professionals in his field, including Lorrie P. Daggett and Steven B. Ellis. These collaborations have further enriched his research and innovation endeavors.

Conclusion

Chin-Chun Lu's work exemplifies the spirit of innovation in the medical field, particularly in addressing hearing loss through novel compounds and methods. His contributions continue to pave the way for future advancements in treatment options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…